A DOUBLE-BLIND, MULTI-CENTRE CONTROLLED TRIAL OF 0.025-PERCENT OXYMETAZOLINE OPHTHALMIC SOLUTION IN PATIENTS WITH ALLERGIC AND NON-INFECTIOUS CONJUNCTIVITIS

  • 1 January 1980
    • journal article
    • research article
    • Vol. 2  (6) , 353-356
Abstract
Oxymetazoline (0.025%) ophthalmic solution, 2 drops, 4 times daily, was compared with a placebo in the treatment of allergic and noninfectious conjunctivitis. In this 1 wk, double-blind, multicenter study, oxymetazoline [sympathomimetic vasoconstrictor] proved significantly superior to the placebo (P < 0.001) in providing rapid and sustained clearing of inflamed conjunctiva. Overall, 84% of allergic patients treated with oxymetazoline were improved, compared to 58% on placebo. Patients with noninfectious conjunctivitis exhibited a high degree of improvement (94%), compared to placebo (51%).

This publication has 0 references indexed in Scilit: